Publications by authors named "Hayden Storts"
Article Synopsis
- FOLFOX, a chemotherapy regimen for colorectal cancer, triggers DNA damage and enhances immune responses through cGAS/STING signaling, increasing inflammation and CD8 T cell presence.
- While 5-FU and oxaliplatin promote immune activity, they also raise PD-L1 levels, which can inhibit T cell function and allow tumors to evade detection.
- Combining FOLFOX with anti-PD-1 treatments shows promise in improving treatment outcomes, as it reduces tumor growth more effectively than FOLFOX alone.
Colorectal cancer is the second leading cause of cancer mortality in the United States. Although immune checkpoint blockade therapies including anti-PD-1/PD-L1 have been successful in treating a subset of patients with colorectal cancer, the response rates remain low. We have found that riluzole, a well-tolerated FDA-approved oral medicine for treating amyotrophic lateral sclerosis, increased intratumoral CD8+ T cells and suppressed tumor growth of colon cancer cells in syngeneic immune-competent mice.
View Article and Find Full Text PDFUnlabelled: The cGAS/STING cytosolic DNA-sensing pathway plays a significant role in antitumor immunity. Expression of STING is tightly regulated and commonly reduced or defective in many types of cancer. We have identified SIX4 as a significant regulator of STING expression in colon cancer cells.
View Article and Find Full Text PDF